Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime

Journal of Antimicrobial Chemotherapy

Volumn 49, Issue 3, 2002, Pages 445-453

  Ambrosea, Paul G ^a   Owens Jr , Robert C ^b   Garvey, Michael J ^c   Jones, Ronald N ^d  

^a Albany Medical College   (United States)

^b MAINE MEDICAL CENTER   (United States)

^c F F Thompson Hospital   (United States)

^d JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFPIROME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; PIPERACILLIN; TOBRAMYCIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG POTENCY; ENTEROBACTERIACEAE; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM POSITIVE COCCI; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PHARMACODYNAMICS; PNEUMONIA; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; SEPSIS; TREATMENT OUTCOME;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME;

EID: 0036122812     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Predominant pathogens in hospital infections
2. Analysis of 1,186 episodes of gram-negative bacteremia in non-university hospitals: The effects of antimicrobial therapy
3. Infections caused by Pseudomonas aeruginosa
4. Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections
5. Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices
6. Pharmacokinetics of cefepime in subjects with renal insufficiency
7. Disposition of the cephalosporin cefepime in normal and renally impaired subjects
8. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects
9. Effects of age and gender on pharmacokinetics of cefepime
10. Pharmacokinetics of cefepime dihydrochloride arginine in subjects with renal impairment
11. Cost-effective analysis of cefepime compared with ceftazidime in intensive care unit patients with hospital-acquired pneumonia
12. Comparison of strategies using cefpirome and ceftazidime for empiric treatment of pneumonia in intensive care unit patients
13. Low-dosage cefepime as treatment for serious bacterial infections
14. Cefepime pharmacokinetics and clinical response in patients with cystic fibrosis
15. Pharmacokinetics of cefepime in patients with sepsis syndrome
16. Pharmacokinetics of cefepime in patients with respiratory tract infections
17. Bacterial pathogens isolated from patients with blood stream infection: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program
18. Summation: Beta-lactam resistance surveillance in the Asia-Western Pacific region
19. Pharmacodynamics in the study of resistance and establishing in vitro susceptibility break-points: Ready for prime time
20. Clinical response to aminoglycoside therapy: Importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance
21. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic animal model of pseudomonal sepsis
22. Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model
23. Pharmacokinetic/pharmacodynamic parameters: Rationale for dosing in mice and men
24. Antimicrobial pharmacodynamics
25. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
26. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute exacerbations of chronic bronchitis
27. Pharmacodynamic comparisons of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in an in vitro model of infection
28. Continuous vs. discontinuous therapy with penicillin
29. Bactericidal activity of cephalosporins in an in vitro model of simulating serum levels
30. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins
31. The novel cephalosporin is active against vancomycin-intermediate S. aureus (VISA) in the neutropenic mouse thigh model
32. Pharmacodynamics of RWI-333441 (MC-04546) when administered as the L-aspartyl pro-drug RWJ-333442 (MC-04699)
33. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials
34. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae: Analysis of phase-III clinical trials
35. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter spp
36. The use of Monte Carlo simulation to examine the pharmacodynamic variance of drugs: Fluoroquinolone pharmacodynamics against Streptococcus pneumoniae
37. Limitations of single-point pharmacodynamic analysis
38. CDC definitions for nosocomial infections
39. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint
40. Clinical efficacy of cefepime in pneumonia caused by Pseudomonas aeruginosa
41. A randomized trial of cefepime and ceftazidime for the treatment of pneumonia
42. Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin
43. Monotherapy in serious hospital-acquired infections: A clinical trial of ceftazidime vs. imipenem/cilastatin
44. Ceftazidime monotherapy vs. ceftriaxone/tobramycin for serious hospital-acquired gram-negative infections
45. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: Outcome correlations in a prospective study of 200 patients
46. Enterobacter bacteremia: Clinical features and emergence of antibiotic resistance during therapy
47. Monotherapy versus β-lactam-aminoglycoside combination treatment for gram-negative bacteremia: A prospective, observational study
48. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients
49. Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia
50. Ceftazidime in the treatment of serious Pseudomonas aeruginosa sepsis
51. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis center
52. Ceftazidime as single-agent therapy for gram-negative aerobic bacillary osteomyelitis
53. In vitro synergistic activities of tobramycin and selected beta-lactams against 75 gram-negative clinical isolates
54. Comparative activity of cefepime, alone and in combination, against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients
55. Evaluation of several dosing regimens of cefepime, with various simulations of renal function, against clinical isolates of Pseudomonas aeruginosa in a pharmacodynamic infection model
56. Comparative in vitro activity of BMY-28142 alone and in combination with amikacin against clinical strains of Pseudomonas aeruginosa, Staphylococcus aureus, and Enterobacteriaceae
57. Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents
58. Comparison of the bactericidal activity of ciprofloxacin alone and in combination with selected antipseudomonal β-lactam agents against clinical isolates of Pseudomonas aeruginosa
59. Ciprofloxacin in combination with other antimicrobials
60. Cefepime vs. ceftazidime treatment of pyelonephritis: A European, randomized, controlled study of 300 pediatric cases
61. Cefepime vs. cefotaxime in the treatment of pneumonia
62. A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenemcilastatin in the treatment of complicated intra-abdominal infections
63. A non-comparative study of the efficacy and tolerance of cefepime in combination with amikacin in the treatment of severe infections in patients in intensive care
64. International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections
65. Clinical applications of a new parenteral antibiotic in the treatment of severe bacterial infections
66. Comparative evaluation of the cefepime Q12 h dosing schedule as empiric monotherapy in febrile neutropenic patients